BY JIM OMEL In July, 2016 I explained INSIGHT, a truly global study of treatment and outcome data for myeloma patients gathered from around the world. The goal of this ambitious undertaking is to accrue 5000 patients over 3 years and follow their various treatments and outcomes for 5 years (an 8 year study estimated to be complete in July, 2024). It is open to (1) participants who have newly diagnosed multiple myeloma, and (2) participants who have relapsed/refractory multiple myeloma.  The overall inclusion goal is 50% for each sub-type of patient. USA will open 50 accrual sites comprised of 40% academic centers and 60% community centers.  Outside the USA global enrollment for 3000 patients is planned with 5-10 sites in each participating country.  INSIGHT is truly global in scope!

INSIGHT is actively accruing patients in at least 17 of the expected 50 eventual USA sites.  Those open sites are: Little Rock AK, La Jolla CA, Denver CO, Niles IL, Columbia MD, Detroit MI, Charlotte NC, Cincinnati OH, Medford and Portland OR, Greenville SC, Amarillo, Dallas, El Paso, Round Rock and San Antonio TX, and Yakima WA.  Worldwide there are 53 sites open globally  from six countries including Brazil, Greece, Israel, Spain, UK and the US as of 12/19/16.

For further information on the specific sites that are open please call 1-844-ONC-TKDA (1-844-662-8532). Also please make a note that more sites in additional states will continue to open into 2017 so the best way to confirm if a specific site is participating is to call this number. Please listen to Dr. Robert Rifkin at Rocky Mountain Cancer Center explain the INSIGHT trial during a recent interview at ASH 16 in San Diego (see below). Dawn Marie Stull, PharmD, Associate Scientific Director, Global Medical Affairs and Co-lead for INSIGHT MM recently said,

“Takeda Oncology is very excited to launch this global observational study. Sites around the world are opening to accrual and patients are enrolling.  This study will provide important information to health care providers who care for MM patients and to the larger MM community. It will enhance our understanding of how MM patients are treated in the real world and their associated outcomes.   We look forward to additional sites opening in 2017 and to the continued enrollment and participation of MM patients”.

All patients are encouraged to enroll in this important observational study, regardless of whatever treatment you are receiving for myeloma.  Adding de-identified information about the effectiveness of your personal treatment to the growing body of outcome data contained in this study, will make INSIGHT  more valuable for us all. Click here to find the clinical trial: INSIGHT Clinical Trial